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Abstract
The new influenza strain detected in humans in April 2009 has caused the first influenza pandemic of the 21st century. A cross-reactive
antibody response, in which antibodies against seasonal H1N1 viruses neutralized the 2009 pandemic influenza A (H1N1) virus (2009
pH1N1), was detected among individuals aged >60 years. However, factors other than age associated with such a cross-reactive anti-
body response are poorly documented. Our objective was to examine factors potentially associated with elevated pre-exposure viro-
neutralization and hemagglutination-inhibition antibody titers against the 2009 pH1N1. We also studied factors associated with antibody
titers against the 2007 seasonal H1N1 virus. One hundred subjects participating in an influenza cohort were selected. Sera collected in
2008 were analysed using hemagglutination inhibition and viro-neutralization assays for the 2009 pH1N1 virus and the 2007 seasonal
H1N1 virus. Viro-neutralization results were explored using a linear mixed-effect model and hemagglutination-inhibition results using lin-
ear-regression models for interval-censored data. Elevated antibody titers against 2009 pH1N1 were associated with seasonal 2007
H1N1 infection (viro-neutralization, p 0.006; hemagglutination-inhibition, p 0.018). Elevated antibody titers were also associated with
age in the viro-neutralization assay (p <0.0001). Seasonal 2007 H1N1 infection is an independent predictor of elevated pre-exposure
antibody titers against 2009 pH1N1 and may have contributed to lowering the burden of the 2009 pH1N1 pandemic.
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Introduction
In April 2009 a new influenza virus strain, the 2009 pan-
demic influenza A (H1N1) virus (2009 pH1N1), with genes
derived from avian, human and classical swine lineages,
emerged in humans [1]. The virus spread rapidly world-
wide, leading the World Health Organization (WHO) to
declare the first influenza pandemic of the 21st century, in
June 2009. Descriptions of the clinical and epidemiological
characteristics of cases in Mexico, the US and the UK,
where sustained human-to-human transmission occurred,
showed that 75% of confirmed cases involved persons aged
between 10 and 50 years [2], as during seasonal H1N1 epi-
demics [3]. A cross-reactive antibody response, in which
antibodies against seasonal H1N1 viruses neutralized the
2009 pH1N1 virus, was detected in 7% of individuals aged
<30 years and in 30% of those aged >60 years [4–6], sug-
gesting that individuals born before 1957, when H1N1 was
replaced by the H2N2 subtype, might be better protected
against this new viral subtype [7]. This was further sup-
ported by reports of memory type T-cell immune
responses against 2009 pH1N1 in some adults, suggesting
cross-reactivity with influenza H1N1 strains circulating prior
to 1957 [8].
However, factors other than age may be associated with
such a cross-reactive antibody response. In particular, the
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potential protective effect of recent seasonal H1N1 virus
infection against 2009 pH1N1 infection is poorly docu-
mented.
We therefore conducted a cross-sectional study of
selected subjects from a large cohort originally designed to
study recurrent seasonal influenza infection, in order to iden-
tify factors associated with pre-exposure neutralizing and
hemagglutination-inhibition antibody titers against the 2009
pH1N1 virus. To determine the specificity of any predictive
factors thus identified for 2009 pH1N1, we also studied
factors associated with neutralizing and hemagglutination-
inhibition antibody titers against the 2007 seasonal H1N1
virus.
Methods
Study design
The study was nested within a cohort of adult volunteers
followed-up over 3 years. The main research objective of
the cohort was to determine the risk of influenza virus infec-
tion according to the viral strain, host immune status and
environmental factors.
Participants in the cohort were recruited during the
2007–2008 seasonal influenza epidemic (2007–2008) by 36
general practitioners (GPs) located throughout France, dur-
ing a medical visit for influenza-like illness (ILI) or another
acute disorder unrelated to ILI. A stratified sampling proto-
col was used. The strata were defined by age (10-year age
groups from 20 to 79 years), and by the reasons for seeking
medical advice (ILI or another acute disorder). ILI was
defined by abrupt onset of fever above 38C, stiffness and
cough. Each GP was asked to include one or two subjects
within each of the 12 strata. Follow-up medical visits took
place at 1-year intervals, with additional medical visits for any
episode of ILI. The cohort study is planned to end in Sep-
tember 2011.
The study was approved by the Ile de France V ethics
committee (#07715) and the French Data Protection
Authority (#1261460). Each participant gave his or her writ-
ten informed consent.
Three hundred and seventy-nine subjects (165 with a diag-
nosis of ILI, 214 with another diagnosis) were recruited dur-
ing the 2007–2008 season (from 7 January to 16 March
2008), of whom 100 were selected for this study. The sam-
ple of 100 participants selected from the cohort was con-
structed to include an equal number of subjects within each
stratum. In keeping with our objectives, participants with a
diagnosis of seasonal H1N1 virus infection were over-repre-
sented in the ILI strata.
Data collection
Data were collected by the GPs during the visits, using a
dedicated electronic case report form.
At inclusion, the reason for the medical visit, chronic ill-
nesses (any condition requiring permanent treatment) and
2007 influenza vaccination status were recorded by the GP.
The 2007 influenza vaccine contained the following strains:
A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005
(H3N2) and B/Malaysia/2506/2004. Nasopharyngeal swabs
(VIROCULT, KITVIA) were collected from participants
with ILI at inclusion, for virological confirmation of influenza.
The sera used in this study were collected during the follow-
up medical visit after the 2007–2008 influenza season,
between 22 May and 10 October 2008.
Laboratory studies
RT-PCR. Nasopharyngeal swabs collected during medical vis-
its for ILI were placed in transport medium and kept at 2–
4C. All samples were centralized in the Virology Laboratory
of Necker Hospital (Paris). One-step RT-PCR was used for
separate amplification of influenza A and B viruses (see Sup-
porting Information).
The influenza viruses that circulated during the 2007–2008
season were A/Brisbane/59/2007 (H1N1) (61%), B/Florida/4/
2006 (36%) and A/Brisbane/10/2007 (H3N2) (3%) [9].
Participants who were PCR-positive for seasonal 2007
H1N1 virus infection were classified as 2007 H1N1-positive,
and others as 2007 H1N1-negative. Participants who were
PCR-positive for seasonal 2007 type B virus infection
were classified as 2007 B-positive, and others as 2007 B-neg-
ative.
Viro-neutralization (VN) and hemagglutination inhibition (HI)
assays. All sera were tested in VN and HI assays (see Sup-
porting Information).
The blood samples were tested for antibodies against
2009 pH1N1 by using the A/New Mexico/04/2009
strain in the VN assay and the OPYFLU-1 strain in the HI
assay.
Antibodies against the 2007 seasonal H1N1 virus were
detected by using the A/Brisbane/59/2007 strain in the VN
assay and the Marseille 2007 strain in the HI assay.
Serial two-fold dilutions of 1/10-diluted sera were pre-
pared, from 1/20 to 1/5120.
The VN assay used virus-like particles (EPIXIS SA, Lyon,
France) [10]. Sera were heat-inactivated for 30 min at 56C
and tested in triplicate. The percentage of viro-neutralization
(PN) was calculated for each triplicate. All values (n = 3)
recorded for each VN assay dilution (n = 8) were taken into
account.
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For the HI assay, the titration endpoint was the highest
dilution that exhibited complete inhibition of hemagglutina-
tion in two independent readings [11].
Statistical methods
The main outcome measure was the percentage of viro-
neutralization at each dilution. Based on a posteriori analysis
and estimates of response variability (effect size of 0.6), the
sample size had more than 90% power to identify factors
associated with PN [12].
Multivariate models were developed to identify factors
associated with PN and/or HI antibody titers. The following
variables were included in the multivariate models: age, sex,
2007 influenza vaccination, 2007 H1N1 status, 2007 B status,
any respiratory illness that occurred between January and
July 2008 after the inclusion episode, and the serum dilution
(VN analysis only). As in previous studies [5], age was cate-
gorized into two groups: 20–49 years and 50–79 years. An
interaction between the age group and 2007 H1N1 status
was tested for in the models.
To identify factors associated with the PN, we used linear
mixed-effect models that took into account the hierarchical
structure of PN data (see Supporting Information). The mod-
els included three random effects, taking into account corre-
lations among triplicates at a given dilution, among different
dilutions for a given participant (nested effect) and a residual
variation [13].
We used linear regression models for interval-censored
data to identify factors associated with the HI antibody titer
[14,15].
Geometric mean titers (GMTs) were calculated for HI
assays as described in [16]. The non-parametric Wilcoxon
rank sum test was used to compare GMTs between age
groups and between 2007 H1N1-positive and negative
subjects. Spearman’s correlation was used to test the associ-
ation between pandemic and seasonal PN or HI antibody
titers. Statistical tests were two tailed, with a type I error
of 5%.
SAS software version 9.1 (SAS Institute, Inc., Cary, NC,
USA) was used for all analyses.
Results
The mean age was 51 years (SD = 16), 47 (47%) of the par-
ticipants were under 50, and 53 participants (53%) were
women. Fifty participants (50%) had chronic illnesses; of
these, 11 were receiving statins, nine were receiving betab-
lockers and four were receiving steroids. Fifty-one partici-
pants (51%) had ILI at inclusion; of these, 35 were positive
for 2007 H1N1, seven were positive for 2007 B, and nine
were negative for both 2007 H1N1 and B. Of the 35 partici-
pants who were positive for the 2007 H1N1, 25 (71%) were
under 50.
Subsequent respiratory illness, between January and June
2008, was reported in 10 participants (10%). Forty partici-
pants (40%) had received the 2007 influenza vaccine.
The PN against 2009 pH1N1 was positively associated
with age and 2007 H1N1 positivity (Table 1). The interaction
between these two covariates was not significant (p 0.88).
The PN was highest in 50- to 79-year-old 2007 H1N1-
positive subjects and lowest in 20- to 49-year-old 2007
H1N1-negative subjects, with an average difference of 20.6%
between these two groups (p <0.0001) (Fig. 1).
The PN differences between the four groups of partici-
pants (20- to 49-year-old 2007 H1N1-positive, 20- to 49-
year-old 2007 H1N1-negative, 50- to 79-year-old 2007
H1N1-positive, 50- to 79-year-old 2007 H1N1-negative)
were statistically significant for each serum dilution
(p <0.0001) (Fig. 1).
TABLE 1. Factors associated with the percentage of viro-neutralization and with hemagglutination antibody titers against the
2009 pandemic influenza A (H1N1) virus
Viro-neutralization assaya Hemagglutination assayb
Coefficient Standard error p-value Coefficient Standard error p-value
Sex (male vs. female) )0.052 0.19 0.79 0.093 0.096 0.33
Age group (50–79 vs. 20–49) 0.82 0.22 0.0003 0.013 0.11 0.91
Influenza vaccination 2007 (yes vs. no) 0.21 0.23 0.37 0.16 0.12 0.16
2007 H1N1 status (positive vs. negative) 0.63 0.23 0.0080 0.26 0.11 0.019
2007 B status (positive vs. negative) 0.34 0.38 0.37 )0.038 0.18 0.98
Respiratory illness, winter 2007–2008 (yes vs. no) 0.11 0.32 0.74 )0.071 0.15 0.64
aEstimates from a multivariate linear mixed-effects model (see manuscript and Supporting Information for details) A positive (or negative) significant coefficient indicates a
positive (or negative) association between the tested factors and the percentage of neutralization, adjusted for all other factors presented in the table.
bEstimates from a multivariate regression model for interval-censored data. A positive (or negative) significant coefficient indicates a positive (or negative) association between
the tested factors and the H1 titer adjusted for all other factors presented in the table.
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Elevated HI antibody titers against the 2009 pH1N1 virus
were associated with 2007 H1N1 positivity but not with age
(Table 1).
The GMT of HI antibodies against the 2009 pH1N1 virus
did not differ according to age (p 0.93) but was higher in
participants who were 2007 H1N1-positive (GMT, 42; 95%
CI, 36–49) than in participants who were 2007 H1N1-nega-
tive (GMT, 37; 95% CI, 32–43), p 0.043.
PN and HI titers against the 2007 seasonal H1N1 virus
were positively associated with 2007 H1N1 positivity and
with 2007 influenza vaccination but did not differ according
to the age group (PN, p 0.063; HI, p 0.31) (Table 2).
The GMT of HI antibodies against the 2007 seasonal
H1N1 virus was higher in participants who were positive for
2007 H1N1 (162; 95% CI, 127–206) than in participants who
were 2007 H1N1-negative (75; 95% CI, 63–90) (p <0.0001).
We found a negative association between PN against the
2007 seasonal H1N1 virus and B infection (p 0.037), which
was due to a single participant with a low level of PN: when
the analysis was repeated without this participant, the
regression coefficient was no longer significant (p 0.096).
We did not found any association between PN and HI
titers against the 2009 pA/H1N1 virus or 2007 seasonal
H1N1 virus and treatment for chronic illness (p >0.20).
PN and HI antibody titers correlated positively with each
other (2009 pH1N1 virus, p 0.0017; 2007 seasonal H1N1
virus, p 0.0015).
Antibody titers against the 2009 pH1N1 virus also corre-
lated with titers against the 2007 seasonal H1N1 virus (PN,
r = 0.70, p <0.0001; HI, r = 0.27, p 0.0056).
Four of the 100 participants selected for this study
reported influenza-like illness during the 2009 pandemic sea-
son; only one was positive for the 2009 pH1N1. This partici-
pant, 25 years of age, was negative for the 2007 H1N1 and
had not received the 2007–2008 seasonal vaccination. PN on
his sera in the present study (collected in June 2008) was
very low (<30%) against the seasonal 2007 H1N1 and 2009
pH1N1. Compared with the three negative patients, this
patient presented the highest number of symptoms and the
longest sick leave from work.
Discussion
In sera collected between May and October 2008, we found
that the PN against the 2009 pH1N1 virus increased with
age. This relationship was expected, and suggests that expo-
sure to H1N1 viruses that circulated before 1957 may have
conferred substantial cross-protective immunity to the 2009
pH1N1 virus [4–7]. In particular, because the immune
20–49 years, H1N1 2007 positive
20–49 years, H1N1 2007 negative
50–79 years, H1N1 2007 positive
50–79 years, H1N1 2007 negative
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FIG. 1. Percentage of viro-neutralization (PN) against the 2009 pan-
demic influenza A (H1N1) virus according to age and 2007 H1N1
status. The PN differed across the curves at each dilution
(p <0.0001).
TABLE 2. Factors associated with the percentage of viro-neutralization and with hemagglutination antibody titers against the
2007 seasonal H1N1 virus
Viro-neutralization assaya Hemagglutination assayb
Coefficient Standard error p-value Coefficient Standard error p-value
Sex (male vs. female) 0.15 0.28 0.60 0.26 0.14 0.064
Age group (50–79 vs. 20–49) 0.61 0.31 0.054 )0.16 0.17 0.34
Influenza vaccination 2007 (yes vs. no) 0.72 0.33 0.035 0.46 0.17 0.0075
2007 H1N1 status (positive vs. negative) 0.74 0.33 0.028 1.04 0.17 <0.0001
2007 B status (positive vs. negative) )1.14 0.54 0.037 0.17 0.25 0.50
Respiratory illness, winter 2007–2008 (yes vs. no) )0.76 0.46 0.10 0.32 0.23 0.16
aEstimates from a multivariate linear mixed-effects model (see manuscript and Supporting Information for details) A positive (or negative) significant coefficient indicates a
positive (or negative) association between the tested factors and the percentage of neutralization, adjusted for all other factors presented in the table.
bEstimates from a multivariate regression model for interval-censored data. A positive (or negative) significant coefficient indicates a positive (or negative) association between
the tested factors and the H1 titer adjusted for all other factors presented in the table.
CMI Lemaitre et al. Pre-exposure antibodies against the 2009 pH1N1 virus 735
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 732–737
response is greatest to antigens to which exposure occurred
first in childhood (the so called ‘original antigenic sin’
[17,18]), old people may differ from young people regarding
immune status against the 2009 pH1N1 virus if influenza
strains with antigenic properties closely related to the 2009
pH1N1 have been circulating in the past.
However, elevated PN and HI antibody titers against the
2009 pH1N1 virus were also positively associated with sea-
sonal 2007 H1N1 influenza infection. This relationship has
not previously been reported in humans but is consistent
with results obtained in a guinea pig model, in which prior
exposure to H1N1 and H3N2 seasonal influenza A strains
provided partial immunity against 2009 pH1N1 infection
[19]. This finding is supported by evidence that memory
cytotoxic T lymphocytes established by seasonal influenza A
viruses had cross-reactivity against 2009 pH1N1 [20].
During the 2009 pH1N1 pandemic, one study participant,
25 years of age and negative for the 2007 H1N1, was posi-
tive for the 2009 pH1N1. PN on his sera in the present
study (collected in June 2008) was very low against the sea-
sonal 2007 H1N1 and the 2009 pH1N1. However, this single
case was not sufficient to draw conclusions on a trend
regarding the rate of infection or clinical severity of the 2009
pH1N1 pandemic in relation to the pre-exposure antibody
titers against the 2009 pH1N1.
Seasonal 2007–2008 influenza vaccination was not associ-
ated with elevated PN or HI antibody titers against the 2009
pH1N1 virus but, as expected, was associated with elevated
PN and HI antibody titers against the 2007 seasonal H1N1
virus. This finding is consistent with previous reports [5,21]
and suggests that immunity to HA protein elicited by vacci-
nation does not cross-protect against viruses bearing variant
HA molecules [22]. Alternatively, the breadth and intensity
of the antibody response to natural infection may be greater
than that elicited by inactivated viral particles.
PN and the HI antibody titer against the 2007 seasonal
H1N1 virus were both positively associated, as expected,
with 2007 H1N1 infection. It is noteworthy that they were
also associated with 2007–2008 seasonal influenza vaccina-
tion. We also found that the HI antibody titer against the
2007 seasonal H1N1 virus was higher in 2007 H1N1-positive
subjects but did not increase with age. The lack of associa-
tion between age and the PN or HI antibody titer against
the 2007 seasonal H1N1 virus was not surprising, as the
participants were stratified for ILI during winter 2007: as ILI
was mostly caused by the 2007 seasonal H1N1 virus and
because infection was logically associated with high antibody
response to this strain, the stratification led to similar
numbers of participants with high or low titers in each age
group.
We chose to explore factors related to PN and HI antibody
titers by using regression models rather than by studying fac-
tors associated with a seroprotection rate, for two reasons.
First, no seroprotection rate has been defined for neutraliza-
tion assays, and second, the statistical power of our study
would have been undermined if the participants had been
categorized around an arbitrary seroprotection threshold.
In conclusion, age and recent exposure to seasonal H1N1
viruses may have independently contributed to the unexpect-
edly low morbidity and mortality of the 2009 pH1N1 pan-
demic.
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